Statins exhibit anticancer effects through modifications of the pAkt signaling pathway

International Journal of Oncology

Volumn 40, Issue 3, 2012, Pages 867-875

  Miraglia, Erica ^a   Högberg, Johan ^a   Stenius, Ulla ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cancer; Chemoprevention; P2X7; pAkt; Statins

Indexed keywords

ACTIN; ATORVASTATIN; BETA CATENIN; ETOPOSIDE; FLUOROURACIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2; PROTEIN KINASE B; PROTEIN P110; PURINERGIC P2X4 RECEPTOR; PURINERGIC P2X7 RECEPTOR; UBIQUITIN PROTEIN LIGASE NEDD4;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SUBPOPULATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; DNA DAMAGE; ETOPOSIDE; FLUOROURACIL; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOPROTEIN PHOSPHATASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; PYRROLES; RECEPTORS, PURINERGIC P2X; SIGNAL TRANSDUCTION;

EID: 84855885011     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1223     Document Type: Article

References (45)

1. Shepherd J, Cobbe SM, Ford I, et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301-1307, 1995.
2. Collins R, Armitage J, Parish S, et al: Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361: 2005-2016, 2003.
3. Solomon KR and Freeman MR: Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol Metab 19: 113-121, 2008. (Pubitemid 351608305)
4. Demierre MF, Higgins PD, Gruber SB, et al: Statins and cancer prevention. Nat Rev Cancer 5: 930-942, 2005. (Pubitemid 41766782)
5. Platz EA, Leitzmann MF, Visvanathan K, et al: Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98: 1819-1825, 2006. (Pubitemid 46017933)
6. Ghosh-Choudhury N, Mandal CC, Ghosh-Choudhury N, et al: Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. Cell Signal 22: 749-758, 2010.
7. Dellavalle RP, Nicholas MK and Schilling LM: Melanoma chemoprevention: a role for statins or fibrates? Am J Ther 10: 203-210, 2003.
8. Poynter JN, Gruber SB, Higgins PD, et al: Statins and the risk of colorectal cancer. N Engl J Med 352: 2184-2192, 2005. (Pubitemid 40727085)
9. Hamilton RJ and Freedland SJ: Review of recent evidence in support of a role for statins in the prevention of prostate cancer. Curr Opin Urol 18: 333-339, 2008. (Pubitemid 351489386)
10. Khurana V, Sheth A, Caldito G and Barkin JS: Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans. Pancreas 34: 260-265, 2007. (Pubitemid 46294804)
11. Brunsveld L, Kuhlmann J, Alexandrov K, et al: Lipidated ras and rab peptides and proteins - synthesis, structure, and function. Angew C http://www.hlektronikotsigaro.gr/ hem Int Ed Engl 45: 6622-6646, 2006.
12. Denoyelle C, Vasse M, Körner M, et al: Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22: 1139-1148, 2001. (Pubitemid 32737327)
13. Mistafa O, Hogberg J and Stenius U: Statins and ATP regulate nuclear pAkt via the P2X7 purinergic receptor in epithelial cells. Biochem Biophys Res Commun 365: 131-136, 2008. (Pubitemid 350102463)
14. Mistafa O, Ghalali A, Kadekar S, Högberg J and Stenius U: Purinergic receptor-mediated rapid depletion of nuclear phosphorylated Akt depends on pleckstrin homology domain leucine-rich repeat phosphatase, calcineurin, protein phosphatase 2A, and PTEN phosphatases. J Biol Chem 285: 27900-27910, 2010.
15. Mistafa O and Stenius U: Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells. Biochem Pharmacol 78: 1115-1126, 2009.
16. Fresno Vara JA, Casado E, De Castro J, et al: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30: 193-204, 2004.
17. Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002. (Pubitemid 37328931)
18. West KA, Castillo SS and Dennis PA: Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 5: 234-248, 2002. (Pubitemid 36132805)
19. Qiao M, Sheng S and Pardee AB: Metastasis and AKT activation. Cell Cycle 7: 2991-2996, 2008.
20. Salmena L, Carracedo A and Pandolfi PP: Tenets of PTEN tumor suppression. Cell 133: 403-414, 2008. (Pubitemid 351622014)
21. Freemantle SJ, Spinella MJ and Dmitrovsky E: Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 22: 7305-7315, 2003. (Pubitemid 37487162)
22. Roudier E, Mistafa O and Stenius U: Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signalling and sensitize p53-deficient cells to cytostatic drugs. Mol Cancer Ther 5: 2706-2715, 2006. (Pubitemid 44848997)
23. Barth K, Weinhold K, Guenther A, et al: Caveolin-1 influences P2X7 receptor expression and localization in mouse lung alveolar epithelial cells. FEBS J 274: 3021-3033, 2007. (Pubitemid 46849079)
24. Barth K, Weinhold K, Guenther A, et al: Characterization of the molecular interaction between caveolin-1 and the P2X receptors 4 and 7 in E10 mouse lung alveolar epithelial cells. Int J Biochem Cell Biol 40: 2230-2239, 2008.
25. Guo C, Masin M, Qureshi OS and Murrell-Lagnado RD: Evidence for functional P2X4/P2X7 heteromeric receptors. Mol Pharmacol 72: 1447-1456, 2007. (Pubitemid 350146082)
26. Casas-Pruneda G, Reyes JP, Pérez-Flores G, et al: Functional interactions between P2X4 and P2X7 receptors from mouse salivary epithelia. J Physiol 587: 2887-2901, 2009.
27. Wang X, Trotman LC, Koppie T, et al: NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128: 129-139, 2007. (Pubitemid 46048884)
28. Brognard J, Sierecki E, Gao T and Newton AC: PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 25: 917-931, 2007. (Pubitemid 46436532)
29. Gao T, Furnari F and Newton AC: PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18: 13-24, 2005. (Pubitemid 40444644)
30. Marqués M, Kumar A, Poveda AM, et al: Specific function of phosphoinositide 3-kinase beta in the control of DNA replication. Proc Natl Acad Sci USA 106: 7525-7530, 2009.
31. Chandrasekar B, Boylston WH, Venkatachalam K, et al: Adiponectin blocks interleukin-18-mediated endothelial cell death via APPL1-dependent AMP-activated protein kinase (AMPK) activation and IKK/NF-kappaB/PTEN suppression. J Biol Chem 283: 24889-24898, 2008.
32. Zabalgoitia M, Colston JT, Reddy SV, et al: Carbon monoxide donors or heme oxygenase-1 (HO-1) overexpression blocks interleukin-18-mediated NF-kappaB-PTEN-dependent human cardiac endothelial cell death. Free Radic Biol Med 44: 284-298, 2008.
33. Pontes J Jr, Srougi M, Borra PM, et al: E-cadherin and beta-catenin loss of expression related to bone metastasis in prostate cancer. Appl Immunohistochem Mol Morphol 18: 179-184, 2010.
34. Cadigan KM: Wnt-beta-catenin signalling. Curr Biol 18: R943-R947, 2008.
35. Michel V and Bakovic M: Lipid rafts in health and disease. Biol Cell 99: 129-140, 2007. (Pubitemid 46380925)
36. Romashkova JA and Makarov SS: NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401: 86-90, 1999.
37. Greer EL and Brunet A: FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24: 7410-7425, 2005. (Pubitemid 41637981)
38. Veilleux A, Houde VP, Bellmann K and Marette A: Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes. Mol Endocrinol 24: 766-778, 2010.
39. Meier R, Alessi DR, Cron P, et al: Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase Bβ. J Biol Chem 272: 30491-30497, 1997. (Pubitemid 27512261)
40. Syed NA, Horner KN, Misra V and Khandelwal RL: Different cellular localization, translocation, and insulin-induced phosphorylation of PKBα in HepG2 cells and hepatocytes. J Cell Biochem 86: 118-127, 2002.
41. Shen Q, Stanton ML, Feng W, et al: Morphoproteomic analysis reveals an overexpressed and constitutively activated phospholipase D1-mTORC2 pathway in endometrial carcinoma. Int J Clin Exp Pathol 4: 13-21, 2010.
42. Trotman LC, Alimonti A, Scaglioni PP, et al: Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441: 523-527, 2006. (Pubitemid 44050155)
43. Zhu Q, Youn H, Tang J, et al: Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers. Oncogene 27: 4569-4579, 2008.
44. Rajpathak SN, Kumbhani DJ, Crandall J, et al: Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 32: 1924-1929, 2009.
45. Vasconsuelo A, Milanesi L and Boland R: 17Beta-estradiol abrogates apoptosis in murine skeletal muscle cells through estrogen receptors: role of the phosphatidylinositol 3-kinase/Akt pathway. J Endocrinol 196: 385-397, 2008. (Pubitemid 351298524)